On November 8, 2021 Bayer Pharmaceuticals, working with The Life Raft Group (LRG), reported that they have extended a research collaboration to broaden access to comprehensive genomic testing for Gastrointestinal Stromal Tumor (GIST) patients (Press release, Bayer, NOV 8, 2021, View Source [SID1234594768]). This collaboration aims to advance precision medicine in oncology and use comprehensive genomic testing to identify patients in the United States (U.S.) who may benefit from personalized care.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Comprehensive genomic testing, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in establishing a GIST diagnosis. There are different types of comprehensive genomic testing: the most common tests are basic mutational testing and advanced next-generation sequencing. These tests may help identify alterations, or changes, within DNA and/or RNA of cancer cells that determine how a tumor behaves or why it grows. Basic mutational testing focuses on testing specific genes like c-KIT, PDGFRA, and BRAF. Advanced next-generation sequencing may test a broader range of genes, usually between 5 – 500+ genes, including neurotrophic receptor tyrosine kinase (NTRK) gene fusions. The results can help healthcare providers match patients with available treatment options or clinical trials. Finding the right therapeutic can be a turning point in the treatment journey of a GIST patient.
GISTs are a type of soft tissue sarcoma – cancers that develop in connective or supporting tissues – that affect an estimated 3,000 to 5,000 people in the U.S. each year.1 One genomic alteration that can drive the growth and spread of GIST is called an NTRK gene fusion. There are currently treatments for GIST driven by NTRK gene fusions approved in the U.S.
Criteria for patients to participate in this program include: be a U.S. resident, be or become a part of The Life Raft Group GIST Patient Registry, have a treating oncologist, must not have had any type of prior comprehensive genomic testing (basic mutational testing or next-generation sequencing), or have previously been identified with wildtype c-KIT or PDGFRA results from basic mutational testing.
The Life Raft Group, based in Wayne, New Jersey, is a global leader in GIST, focused on educating patients, providing resources, and launching initiatives for the community for better patient outcomes. This collaboration is an example of the vital role patient advocacy groups play in bridging the gap between researchers and motivated patient populations willing to be part of innovative studies.
"As part of our commitment to precision oncology, we believe identifying NTRK patients early through comprehensive genomic testing is a critical step in the cancer diagnosis of oncology patients experiencing metastatic disease, as it helps physicians understand the underlying drivers of tumor growth and can inform the treatment approach," said Iain Webb, M.D., Vice President, U.S. Medical Affairs, Oncology at Bayer. "That is why we are pleased to collaborate with The Life Raft Group to increase the availability of comprehensive genomic testing for GIST patients to potentially uncover NTRK gene fusions and provide options for those who may benefit from precision oncology treatments."
This collaboration builds on Bayer’s existing commitment to advance precision oncology, which includes research to find targets and pathways that drive cancer growth, and how these findings can impact the way cancer is treated.
"We are excited to be a part of this groundbreaking opportunity to work with great organizations to pave the road towards precision medicine and to help us to reach our goal of increasing the testing rate among GIST patients," said Denisse Montoya, Patient Registry Director at The Life Raft Group. "By offering comprehensive genomic testing with no charge, many patients will have the opportunity to know what genes are driving their GIST and benefit from genetic-informed care. Results from this testing collaboration will help us understand more traits and patterns within GIST that will help us with our aim of accelerating GIST cancer research."
Healthcare professionals with eligible patients can find additional information here.